Clinical studies of asthma treatments

Thematic Poster
Chairs: S. Jabbal (Dundee (Angus), United Kingdom), P. Berger (Bordeaux, France), A. Schuster (Düsseldorf, Germany)

Curcumin Improves Therapy of Moderate Partially Controlled Asthma: Placebo-controlled, single blind study E. Jusufovic (Tuzla, Bosnia and Herzegovina), M. Kosnik (Ljubljana, Slovenia), J. Nurkic (Tuzla, Bosnia and Herzegovina), N. Arifhodzic (Kuwait, Kuwait), M. Al-Ahmad (Kuwait, Kuwait), L. Bulat-Kardum (Rijeka, Croatia), M. Becarevic (Tuzla, Bosnia and Herzegovina), M. Osmic (Tuzla, Bosnia and Herzegovina), A. Nadarevic (Tuzla, Bosnia and Herzegovina), A. Jusufovic (Tuzla, Bosnia and Herzegovina), D. Halilovic (Tuzla, Bosnia and Herzegovina), R. Sejdinovic (Tesanj, Bosnia and Herzegovina), S. Brekalo (Tuzla, Bosnia and Herzegovina), B. Prnjavorac (Tesanj, Bosnia and Herzegovina)
A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy), P. Rogliani (Rome, Italy), E. Puxeddu (Rome, Italy), M. Matera (Naples, Italy)
Interval Exercise Training in Poorly Controlled Asthma: Preliminary Clinical Trial Results A. Freeman (Southampton, United Kingdom), R. Geale (Southampton, United Kingdom), S. Bali (Southampton, United Kingdom), K. Gove (Southampton, United Kingdom), D. Cellura (Southampton, United Kingdom), H. Burke (Southampton, United Kingdom), T. Wallis (Southampton, United Kingdom), K. Paas (Southampton, United Kingdom), K. Staples (Southampton, United Kingdom), S. Jack (Southampton, United Kingdom), M. Grocott (Southampton, United Kingdom), T. Wilkinson (Southampton, United Kingdom)
Montelukast induces better control of symptoms and management of lung function, and decreased inflammation in women compared with men. G. Spaziano (NAPLES, Italy), F. Polverino (TUCSON, United States of America), D. Giannattasio (Scafati, Italy), F. Ferrigno (Scafati, Italy), M. Sessa (Copenhagen, Denmark), A. Rossi (NAPLES, Italy), F. Roviezzo (NAPLES, Italy), M. Polverino (Scafati, Italy), B. D'Agostino (NAPLES, Italy)
Does long-term macrolide treatment reduce asthma exacerbations? An individual patient data meta-analysis S. Hiles (Newcastle, Australia), V. Mcdonald (Newcastle, Australia), M. Guilhermino (Newcastle, Australia), G. Brusselle (Ghent, Belgium), P. Gibson (Newcastle, Australia)
Towards optimal patient selection for bronchial thermoplasty treatment in severe asthma: results from the TASMA randomized trial A. Goorsenberg (Amsterdam, Netherlands), J. D'Hooghe (Amsterdam, Netherlands), N. Ten Hacken (Groningen, Netherlands), E. Weersink (Amsterdam, Netherlands), E. Bel (Amsterdam, Netherlands), P. Shah (London, United Kingdom), J. Annema (Amsterdam, Netherlands), P. Bonta (Amsterdam, Netherlands)
Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study W. Cheng (Taichung, Taiwan), B. Wu (Taichung, Taiwan), C. Chen (Taichung, Taiwan), W. Chen (Taichung, Taiwan), W. Liao (Taichung, Taiwan), C. Tu (Taichung, Taiwan), C. Chen (Taichung, Taiwan)
Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland)
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects H. Tillmann (Basel, Switzerland), B. Ethell (Cambridge, United States of America), N. Abdallah (Basel, Switzerland), S. Machineni (Hyderabad, India), A. Drollmann (Basel, Switzerland), S. Last (Berlin, Germany), M. Hahn (Basel, Switzerland), R. Radhakrishnan (Hyderabad, India), S. Ignatenko (Berlin, Germany), S. Vaidya (Cambridge, United States of America)
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate as a fixed-dose combination in Japanese and Caucasian healthy subjects H. Tillmann (Basel, Switzerland), S. Inoue (Tokyo, Japan), S. Vaidya (Cambridge, United States of America), Y. Sakita (Tokyo, Japan), S. Machineni (Hyderabad, India), K. Kobayashi (Tokyo, Japan), K. Furihata (Tokyo, Japan)
Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma patients D. Miller (North Dartmouth, United States of America), J. Jauernig (Basel, Switzerland), S. Vaidya (Cambridge, United States of America), B. Ethell (Cambridge, United States of America), K. Wagner (East Hannover, United States of America), R. Radhakrishnan (Hyderabad, India), H. Tillmann (Basel, Switzerland)
Variability in Blood Eosinophils: Findings from the WATCH Cohort of Difficult Asthma A. Azim (Southampton, United Kingdom), N. Colin (Southampton, United Kingdom), C. Barber (Southampton, United Kingdom), A. Freeman (Southampton, United Kingdom), H. Mistry (Southampton, United Kingdom), A. Kyyaly (Southampton, United Kingdom), H. Haitchi (Southampton, United Kingdom), P. Dennison (Southampton, United Kingdom), P. Howarth (Southampton, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom)
Influence of controller therapy with extrafine beclometasone/formoterol on the quality of life of asthma patients with cold and/or osmotic airway hyperresponsiveness N. Perelman (Blagoveshchensk, Russian Federation), A. Prikhodko (Blagoveshchensk, Russian Federation), E. Kochegarova (Blagoveshchensk, Russian Federation), L. Oshur (Blagoveshchensk, Russian Federation), E. Afanaseva (Blagoveshchensk, Russian Federation)
Free serum IgE suppression with omalizumab and clinical outcomes in asthma C. Liu (Chengdu, China), J. Li (Guangzhou, China), J. Yang (Beijing, China), L. Wang (Beijing, China), M. Humphries (Beijing, China), I. Ioannis Kottakis (Bazel, Switzerland), R. Fogel (East Hanover, United States of America), X. Lau (Petaling Jaya, Malaysia), N. Zhong (Guangzhou, China)
Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients F. Nissen (Basel, Switzerland), M. Humbert (Paris, France), P. Gibson (Newcastle, Australia), K. Kostikas (Ioannina, Greece), X. Jaumont (Basel, Switzerland), P. Olsson (Kista, Sweden), L. Alvares (Basel, Switzerland), J. Bousquet (Montigny le Bretonneux, France)
The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks D. Jackson (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), J. Kavanagh (London, United Kingdom), G. D'Ancona (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom)
Durability of mepolizumab treatment response between doses I. Pavord (Oxford, United Kingdom), P. Howarth (Brentford, United Kingdom), D. Bratton (Stockley Park, United Kingdom), F. Albers (Research Triangle Park, United States of America), S. Yancey (Research Triangle Park, United States of America)
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies F. Nissen (Basel, Switzerland), M. Humbert (Paris, France), P. Gibson (Newcastle, Australia), K. Kostikas (Ioannina, Greece), X. Jaumont (Basel, Switzerland), P. Tassinari (Basel, Switzerland), P. Pfister (Basel, Switzerland), J. Bousquet (Montigny le Bretonneux, France)
Effects of Mepolizumab on symptoms, systemic and bronchial inflammation F. Cherubino (Tradate, Italy), G. Bertolotti (Tradate, Italy), A. Ianni (Tradate, Italy), A. De Lauretis (Garbagnate Milanese, Italy), R. Pintucci (Varese, Italy), D. Visca (Varese, Italy), E. Zampogna (Tradate, Italy), P. Pignatti (Pavia, Italy), A. Spanevello (Varese, Italy)